Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16654388 | 0.93 | GAA (0.53) | GAABTKNFKB1NFKB2RELA | |
| SCHEMBL21166486 | 0.93 | GAA (0.49) | GAABTKNFKB1NFKB2RELA | |
| SCHEMBL31731133 | 0.89 | GAA (0.49) | GAABTKNFKB1NFKB2RELA | |
| SCHEMBL14863459 | 0.89 | GAA (0.49) | GAABTKNFKB1NFKB2RELA | |
| SCHEMBL32685245 | 0.89 | GAA (0.49) | GAABTKNFKB1NFKB2RELA | |
| SCHEMBL18595288 | 0.89 | GAA (0.49) | GAABTKNFKB1NFKB2RELA | |
| SCHEMBL20689298 | 0.89 | GAA (0.49) | GAABTKNFKB1NFKB2RELA | |
| SCHEMBL17854941 | 0.89 | GAA (0.49) | GAABTKNFKB1NFKB2RELA | |
| SCHEMBL4697421 | 0.89 | GAA (0.49) | GAABTKNFKB1NFKB2RELA | |
| SCHEMBL26273295 | 0.89 | GAA (0.49) | GAABTKNFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655260-B2 | Heterocyclic compounds as arginase inhibitors | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11655260-B2 | Heterocyclic compounds as arginase inhibitors | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20220251116-A1 | ALKYLBORONIC ACIDS AS ARGINASE INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2022-08-11 | — | — | US | disclosed |
| WO-2020160707-A1 | ALKYLBORONIC ACIDS AS ARGINASE INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655260-B2 | Heterocyclic compounds as arginase inhibitors | ARG1, ARG2, PRMT1 | GAA 458/4885BTK 2525/4885NFKB1 657/4885 |
| US-20220251116-A1 | ALKYLBORONIC ACIDS AS ARGINASE INHIBITORS | ARG1, ARG2, PADI6 | GAA 444/4885BTK 1035/4885NFKB1 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.